• Monday, January 8, 2024 @ 12:00 am

Results of “Study 014/015 of evenamide in treatment-resistant schizophrenia (TRS) continue to surprise with unprecedented efficacy with ~25% of patients achieving remission and >70% experiencing a clinically relevant reduction in disease severity at one year potentially transforming TRS treatment.

Key catalysts include:

1. Results “Study 008A” in non-TRS (March 2024)

2. Partnering evenamide with a major CNS player (H1 2024)

3. Start pivotal “Study 016” trial of evenamide in TRS (end Q2 2024)

Read full Newron valuation report

You may also be interested in